Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Radiographic Improvement in Sarcoid Arthropathy after Infliximab Treatment

BELLA MEHTA and PETROS EFTHIMIOU
The Journal of Rheumatology March 2012, 39 (3) 664-665; DOI: https://doi.org/10.3899/jrheum.111002
BELLA MEHTA
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PETROS EFTHIMIOU
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pe53@cornell.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

To the Editor:

We describe our experience on the use of infliximab in sarcoid arthropathy and partial reversal of the typical radiographic changes seen in sarcoid arthropathy after treatment.

A 35-year-old African American man presented 5 years ago with bilateral hand arthritis, dactylitis, and a shiny, fleshy growth over the tip of the nose. Examination revealed bilateral proximal interphalangeal joint synovitis and severe deformity and resorption of the distal interphalangeal joints with dystrophic nail changes and diffuse dactylitis. The fleshy growth was indicative of a sarcoid-specific “lupus pernio” presentation, confirmed by skin biopsy, showing noncaseating granulomas. Chest radiography showed paratracheal and bilateral hilar lymphadenopathy without parenchymal disease. Laboratory evaluation revealed elevation of erythrocyte sedimentation rate (ESR) and angiotensin converting enzyme (ACE). Hand radiographs showed several circumscribed, corticated digital lytic bone lesions that could be suggestive of intraosseous sarcoid granulomas. A characteristic “lacy reticular” bone pattern, a hallmark of sarcoid arthropathy, with marginal bone erosions, was also seen. He was initially treated with nonsteroidal antiinflammatory drugs (NSAID), oral corticosteroids, and methotrexate (MTX), with minimal clinical response. Intravenous infliximab 5 mg/kg every 8 weeks was added 3 years ago, titrated up to 7 mg/kg after 1 year. Small-joint synovitis of the hands was decreased and ACE levels, ESR, and C-reactive protein levels all normalized. Dactylitis improved and the lupus pernio size decreased with treatment. Infliximab treatment was complicated by transient neutropenia that resolved after withholding 2 consecutive infusions and altering MTX dosage.

Repeat radiographic assessment 3 years after initiation of infliximab and intermittent MTX combination treatment demonstrated disappearance of the lacy reticular pattern and some improvement of the lytic digital lesions. Several lytic bone lesions significantly decreased in size, possibly reflecting granuloma contraction (Figure 1). As well, no new bone erosions were observed in the followup radiograph.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Hand radiographs before (left) and after (right) infliximab treatment. Note decrease in size of lytic bone lesions (arrows) and resolution of lacy reticular pattern (circles).

To our knowledge, this is the first report of reversal of radiographic lesions in sarcoid arthropathy after treatment with infliximab. A report by Huang, et al demonstrated clinical improvement, although with no mention of a radiographic improvement1.

Radiographic findings include lytic lesions. They present either as minute cortical defects or large punched-out cysts involving the heads of middle and proximal phalanges. Lace-like trabecular pattern and cystic changes in the phalangeal joints are characteristic of sarcoid arthropathy. Distal tuft destruction can be seen in advanced cases. Subchondral lesions that extend into joint spaces can lead to joint involvement.

There is a paucity of controlled studies in sarcoid arthritis in regard to treatment. NSAID, corticosteroids, and MTX have all been tried with various degrees of success2.

Several reports have suggested efficacy of the tumor necrosis factor-α (TNF-α) antagonists in refractory sarcoidosis, including sarcoid arthritis, with a potential differential beneficial response to infliximab over the other TNF inhibitors, as well as placebo1,3,4,5,6,7,8. There have also been studies demonstrating that infliximab is superior to systemic corticosteroids in treating lupus pernio9. But there have also been rare reports of paradoxical development of biopsy-proven sarcoidosis after use of TNF antagonist for other indications, which resolved after discontinuation of the biologic agent10. Controlled studies are needed to carefully study infliximab’s efficacy and safety in sarcoid arthropathy.

REFERENCES

  1. 1.↵
    1. Huang A,
    2. Harty LC,
    3. Ryan CM,
    4. Veale DJ
    . Clinical images: Infliximab therapy of polyarticular small joint sarcoid arthritis. Arthritis Rheum 2011;63:2030.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Londner C,
    2. Zendah I,
    3. Freynet O,
    4. Carton Z,
    5. Dion G,
    6. Nunes H,
    7. et al.
    Treatment of sarcoidosis. Rev Med Interne 2011;32:109–13.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Utz JP,
    2. Limper AH,
    3. Kalra S,
    4. Specks U,
    5. Scott JP,
    6. Vuk-Pavlovic Z,
    7. et al.
    Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177–85.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Doty JD,
    2. Mazur JE,
    3. Judson MA
    . Treatment of sarcoidosis with infliximab. Chest 2005;127:1064–71.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Saleh S,
    2. Ghodsian S,
    3. Yakimova V,
    4. Henderson J,
    5. Sharma OP
    . Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006;100:2053–9.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Agrawal S,
    2. Bhagat S,
    3. Dasgupta B
    . Sarcoid sacroiliitis: Successful treatment with infliximab. Ann Rheum Dis 2009;68:283.
    OpenUrlFREE Full Text
  7. 7.↵
    1. Garg S,
    2. Garg K,
    3. Altaf M,
    4. Magaldi JA
    . Refractory vertebral sarcoidosis responding to infliximab. J Clin Rheumatol 2008;14:238–40.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Baughman RP,
    2. Drent M,
    3. Kavuru M,
    4. Judson MA,
    5. Costabel U,
    6. du Bois R,
    7. et al.
    Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795–802.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Stagaki E,
    2. Mountford WK,
    3. Lackland DT,
    4. Judson MA
    . The treatment of lupus pernio: Results of 116 treatment courses in 54 patients. Chest 2009;135:468–76.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Daien CI,
    2. Monnier A,
    3. Claudepierre P,
    4. Constantin A,
    5. Eschard JP,
    6. Houvenagel E,
    7. et al.
    Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology 2009;48:883–6.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 3
1 Mar 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiographic Improvement in Sarcoid Arthropathy after Infliximab Treatment
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Radiographic Improvement in Sarcoid Arthropathy after Infliximab Treatment
BELLA MEHTA, PETROS EFTHIMIOU
The Journal of Rheumatology Mar 2012, 39 (3) 664-665; DOI: 10.3899/jrheum.111002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Radiographic Improvement in Sarcoid Arthropathy after Infliximab Treatment
BELLA MEHTA, PETROS EFTHIMIOU
The Journal of Rheumatology Mar 2012, 39 (3) 664-665; DOI: 10.3899/jrheum.111002
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Herpes Zoster Vaccine and Rheumatoid Arthritis
  • Seasonal Variations and Their Influence on Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Relapse
  • Survival After Lung Transplantation in Patients With Rheumatoid Arthritis-Associated Lung Disease
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire